Reported Adverse Effects of Maunzar in Japan: Hypoglycemia and Pancreatitis After Use for Weight Loss
35 Cases Reported After Use for Dieting and Cosmetic Purposes
In Japan, there has been a series of cases where people have reported adverse effects after using Maunzar, an obesity and diabetes medication, for dieting or cosmetic purposes.
According to Kyodo News on the 22nd, there have been 35 reports of suspected adverse effects related to the use of Maunzar for dieting or cosmetic purposes submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan over the past three years.
In Japan, Maunzar is sold as a treatment for type 2 diabetes and requires a doctor's prescription. However, it has become problematic that people are using it for weight loss through out-of-pocket medical services that are not covered by health insurance, or buying and selling it directly between individuals via social networking services (SNS).
The reported suspected adverse effects include hypoglycemia, pancreatitis, and ketoacidosis—a condition in which the blood becomes acidic. All of these symptoms are listed in the drug's package insert as requiring caution. However, there are also cases among the reports where the causal relationship between the medication and the symptoms is unclear.
It has also been suggested that there may be unreported cases where symptoms were mild. Ogawa Wataru, a professor specializing in obesity treatment at Kobe University, warned, "When trying to lose weight, you should consider whether the method (such as Maunzar) is safe."
In June, Japan’s Ministry of Health, Labour and Welfare sent notifications to medical institutions emphasizing the appropriate use of Maunzar. They warned that its effectiveness for purposes such as dieting has not been proven, and that using it for purposes other than intended could lead to unexpected health risks.
In Korea, a growing number of people have been obtaining prescriptions for Maunzar in Japan, where it is relatively inexpensive, leading to the creation of a new term that combines "sushi" and "Maunzar"—"Sushizaro." Although the price varies by hospital, the local purchase price in Japan is reportedly around 50,000 to 70,000 won. This is about one-fourth to one-fifth of the price in Korea.
In Korea, Maunzar is not covered by health insurance and its price is not regulated by the government. In contrast, Japan manages the drug price for Maunzar as a treatment for type 2 diabetes, which results in a price gap between the two countries.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Illegal import cases of obesity medications are also on the rise. According to the Korea Customs Service, there were 4,155 cases of illegal importation of obesity medications—including Maunzar and Wegovy—between January and June of this year. This figure is approximately 3.5 times higher than the annual total of 1,189 cases detected last year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.